1-15 of 15
Behzad Kharabi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot
Journal: Blood
Blood (2022) 140 (Supplement 1): 3158–3161.
https://doi.org/10.1182/blood-2022-158248
Published: 2022
Journal Articles

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Behzad Kharabi Masouleh, Enrique Granados, Javier Pinilla Ibarz
Journal: Blood
Blood (2022) 140 (Supplement 1): 7454–7456.
https://doi.org/10.1182/blood-2022-167868
Published: 2022
Journal Articles

The Comparison of Kte-X19 to Current Standards of Care: A Pre-Specified Synthetic Control Study Utilizing Individual Patient Level Data from Historic Clinical Trials (SCHOLAR-3)

Bijal D. Shah, Imi Faghmous, James Whitmore, Behzad Kharabi Masouleh, Hairong Xu
Journal: Blood
Blood (2021) 138 (Supplement 1): 3844.
https://doi.org/10.1182/blood-2021-146598
Published: 2021
Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42.
https://doi.org/10.1182/blood-2020-137233
Published: 2020
Journal Articles

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

Iris Appelmann, MD, Azam Salimi, Michael Huber, PhD, Mirle Schemionek, PhD, Margherita Vieri, PhD, Tim H Brümmendorf, MD, John B. Patterson, Behzad Kharabi Masouleh, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-140299
Published: 2020
Journal Articles

Synergistic Dual Inhibition of BCR-ABL1 and the Unfolded Protein Response Causes p38 MAPK-Mediated Cell Death and Sensitizes BCR-ABL1 + Acute Lymphoblastic Leukemia to Dexamethasone

Margherita Vieri, MSc, Christian Preisinger, Mirle Schemionek, Azam Salimi, John B. Patterson, Afshin Samali, Tim H Brümmendorf, MD, Iris Appelmann, MD, Behzad Kharabi Masouleh, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4674.
https://doi.org/10.1182/blood-2018-99-110967
Published: 2018
Journal Articles

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Anas Younes, MD, Joshua Brody, MD, Cecilia Carpio, MD, Armando Lopez-Guillermo, Dina Ben-Yehuda, MD, A. Burhan Ferhanoglu, MD, Arnon Nagler, MD, Muhit Ozcan, MD, Irit Avivi, MD, Francesc Bosch Albareda, MD PhD, María Dolores Caballero Barrigón, MD PhD, Aisha Masood, MD, Michael Streit, MD MBA, John Alvarez, MD PhD, Rob Ceulemans, MS, Behzad Kharabi Masouleh, MD, Sriram Balasubramanian, PhD, Michael Schaffer, PhD, Shean-Sheng Wang, PhD, Nele Fourneau, MD, Wojciech Jurczak, PhDMD
Journal: Blood
Blood (2017) 130 (Supplement 1): 833.
https://doi.org/10.1182/blood.V130.Suppl_1.833.833
Published: 2017
Journal Articles

The Effect of the Proteasome Inhibitor Ixazomib (MLN9708) and UPR Mediated Therapy in Multiple Myeloma Cells and Bone Marrow Niche

Azam Salimi, MSc, Kema Marlen Schroeder, Margherita Vieri, Tim H. Brümmendorf, MD, Iris Appelmann, Behzad Kharabi
Journal: Blood
Blood (2017) 130 (Supplement 1): 5362.
https://doi.org/10.1182/blood.V130.Suppl_1.5362.5362
Published: 2017
Journal Articles

Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia

Lai N Chan, PhD, Daniel Braas, Christian Hurtz, PhD, Seyedmehdi Shojaee, PhD, Behzad Kharabi Masouleh, MD, Huimin Geng, PhD, Thomas Ernst, MD, Andreas Hochhaus, MD, Thomas Graeber, PhD, Markus Muschen, MDPhD
Journal: Blood
Blood (2014) 124 (21): 783.
https://doi.org/10.1182/blood.V124.21.783.783
Published: 2014
Journal Articles

IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia

Huimin Geng, PhD, Jae-Woong Lee, PhD, Zhengshan Chen, MD PhD, Behzad Kharabi Masouleh, MD, Christian Hurtz, PhD, Eugene Park, Gang Xiao, PhD, Samir Parekh, MD, Steven M. Kornblau, MD, Ari Melnick, MD, Elisabeth Paietta, PhD, Markus Muschen, MDPhD
Journal: Blood
Blood (2014) 124 (21): 788.
https://doi.org/10.1182/blood.V124.21.788.788
Published: 2014
Journal Articles

Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia

Huimin Geng, PhD, Christian Hurtz, PhD, Zhengshan Chen, MD, PhD, Wei-Yi Chen, PhD, Erica Ballabio, PhD, Gang Xiao, PhD, Soo-mi Kweon, PhD, Rahul Nahar, PhD, Seyedmehdi Sojaee, PhD, Lai N. Chan, PhD, Behzad Kharabi Masouleh, MD, David B. Sykes, MD, PhD, Ari Melnick, MD, Robert Roeder, PhD, Thomas Milne, PhD, Markus Muschen, MD
Journal: Blood
Blood (2013) 122 (21): 349.
https://doi.org/10.1182/blood.V122.21.349.349
Published: 2013
Journal Articles

The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph + ALL

Behzad Kharabi Masouleh, MD, Huimin Geng, PhD, Christian Hurtz, PhD, Chuanxin Huang, PhD, Lai N. Chan, PhD, Srividya Swaminathan, PhD, Haibo Sun, PhD, H. Phillip Koeffler, MD, Ari Melnick, MD, Elisabeth Paietta, PhD, Laurie H. Glimcher, MD, Markus Muschen, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 836.
https://doi.org/10.1182/blood.V122.21.836.836
Published: 2013
Journal Articles

Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL

Christian Hurtz, PhD, Huimin Geng, PhD, Erica Ballabio, PhD, Gang Xiao, PhD, Carina Ng, Behzad Kharabi Masouleh, MD, Cheryl L. Willman, MD, Scott A. Armstrong, MD, PhD, Thomas Milne, PhD, Ari Melnick, MD, Markus Muschen
Journal: Blood
Blood (2013) 122 (21): 72.
https://doi.org/10.1182/blood.V122.21.72.72
Published: 2013
Journal Articles

Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL

Christian Hurtz, Parham Ramezani-Rad, Huimin Geng, PhD, Behzad Kharabi, MD, William L. Carroll, MD, Cheryl L Willman, MD, Scott A. Armstrong, MD, PhD, Ari Melnick, MD, Markus Muschen, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 776.
https://doi.org/10.1182/blood.V120.21.776.776
Published: 2012
Journal Articles

Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph + ALL

Behzad Kharabi Masouleh, MD, Christian Hurtz, Huimin Geng, PhD, Parham Ramezani-Rad, Laurie H. Glimcher, MD, Markus Muschen, MD
Journal: Blood
Blood (2012) 120 (21): 872.
https://doi.org/10.1182/blood.V120.21.872.872
Published: 2012